Emcure Pharma shares hit 10% upper circuit as Q2 net profit rises

What happened

Emcure Pharmaceuticals shares rose 10 per cent to the upper circuit on Wednesday after the company reported September-quarter consolidated net profit of ₹325.06 crore, up 29.31 per cent year on year. Emcure attributed the increase to strong growth in its international business.

Confirmed

Global impact / market context

Higher profit and the international business contribution suggest stronger earnings are reaching the company’s bottom line. Jefferies also lifted its FY27 revenue growth outlook and expects improved profit per sale, which, if achieved, could support future earnings; these remain brokerage expectations, not reported results.

Analyst inference

The article reports a 10 per cent share-price rise and says brokerages maintained buy ratings, with Jefferies raising its target price and growth estimates. This links the reported quarterly result to investor positioning, while future growth depends on the company delivering domestic recovery and international product expansion.

Analyst inference

What to watch

1. Check whether later quarterly results show international business growth continuing, since the company identified that business as the main support for the reported profit increase. Analyst inference
2. Track progress in expanding Amphotericin B across 20 European countries and the planned Treprostinil launch, which Jefferies cited as supports for international growth. Proposed
3. Compare reported FY27 revenue growth and profit per sale with Jefferies’ expectations of over 20 per cent growth and a 100-basis-point improvement. Analyst inference

Evidence

• Original source link unavailable